Format

Send to

Choose Destination
Eur J Med Chem. 2017 May 26;132:294-309. doi: 10.1016/j.ejmech.2017.03.062. Epub 2017 Mar 27.

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.

Author information

1
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China.
2
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
3
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: sunhaopeng@163.com.

Abstract

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders with notable factor of dysfunction in cholinergic system. Low ACh level can be observed in the pathogenesis of AD. Several AChE inhibitors have already been used for clinical treatments. However, other than normal conditions, ACh is mostly hydrolyzed by BuChE in progressed AD. Account for an increased level of BuChE and decreased level of AChE in the late stage of AD, development of selective BuChE inhibitor is of vital importance. Up till now, compounds with various scaffolds have been discovered to selectively inhibit BuChE. Different effective anti-BuChE molecules are concluded in this review.

KEYWORDS:

Alzheimer's disease; Selective butyrylcholinesterase inhibitors

PMID:
28371641
DOI:
10.1016/j.ejmech.2017.03.062
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center